KUKJEON PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,580 KRW | -0.89% |
|
-1.06% | -10.58% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 104B 75.92M | Sales 2023 | 122B 89.3M | Capitalization | 306B 224M |
|---|---|---|---|---|---|
| Net income 2022 | 8.95B 6.55M | Net income 2023 | 4.82B 3.53M | EV / Sales 2022 | 2.79 x |
| Net cash position 2022 | 35.63B 26.08M | Net Debt 2023 | 13.95B 10.21M | EV / Sales 2023 | 2.62 x |
| P/E ratio 2022 |
583
x | P/E ratio 2023 |
63.7
x | Employees | 160 |
| Yield 2022 * |
-
| Yield 2023 |
0.16% | Free-Float | 38.01% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.89% | ||
| 1 week | -1.06% | ||
| Current month | -1.24% | ||
| 1 month | -4.78% | ||
| 3 months | -4.62% | ||
| 6 months | -4.29% | ||
| Current year | -10.58% |
1 week
5 580.00
6 290.00
1 month
5 420.006 290.00
Current year
5 420.007 090.00
1 year
5 420.008 140.00
3 years
4 230.0024 900.00
5 years
4 230.0024 900.00
10 years
4 230.0024 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Ho Hong
CEO | Chief Executive Officer | 53 | - |
Dong-Woon Kim
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Jong-Hak Lee
BRD | Director/Board Member | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seon-Gyu Choi
BRD | Director/Board Member | 70 | - |
Jong-Ho Hong
CEO | Chief Executive Officer | 53 | - |
Jong-Hak Lee
BRD | Director/Board Member | 53 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 5,580 | -0.89% | 98,059 |
| 24-05-10 | 5,630 | -0.71% | 165,892 |
| 24-05-09 | 5,670 | -1.39% | 236,113 |
| 24-05-08 | 5,750 | +1.95% | 4,162,057 |
End-of-day quote Korea S.E., May 12, 2024
More quotes
Kukjeon Pharmaceutical Co Ltd, formerly Daishin Balance No.6 Special Purpose Acquisition Co Ltd, is a Korea-based company mainly engaged in the manufacture and sale of drug substances. The Company manufactures and sells raw materials used in specialized medicines such as choline alfoscerates, benfothiamines, spherical sorbents, and napamostat mesylatse. The Company sells its products in domestic and overseas markets such as Japan.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -10.58% | 202M | |
| +21.09% | 43.27B | |
| +25.28% | 22.92B | |
| +19.22% | 15.43B | |
| +13.51% | 12.95B | |
| +44.01% | 11.83B | |
| -7.79% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.26% | 5.55B |
- Stock Market
- Equities
- A307750 Stock